Hy Lạp - Tiếng Hy Lạp - Εθνικός Οργανισμός Φαρμάκων

opus materia ΕΠΕ Παλαιολόγου 33,, 175 64 175 64, Π. Φάληρο 0109408420 - bicalutamide - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 150mg/tab - bicalutamide 150mg - bicalutamide

Hy Lạp - Tiếng Hy Lạp - Εθνικός Οργανισμός Φαρμάκων

demo abee - enzymes - ΔΙΣΚΙΑ ΕΝΤΕΡΟΔΙΑΛΥΤΑ ΕΠΙΚΑΛΥΜΕΝΑ ΜΕ ΥΜΕΝΙΟ - 5mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Hy Lạp - Tiếng Hy Lạp - Εθνικός Οργανισμός Φαρμάκων

ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΠΑΣΤΕΡ Βασ.Σοφίας 127,, 115 21 115 21, Αθήνα 6462281, 6430044 - rabies wistar virus pm/w1 38 1503-3Μ inactivated - ps.inj.sus (ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 2,5iu/dose - rabies wistar virus pm/w1 38 1503-3Μ inactivated 2,5iu - rabies, inactivated, whole virus

Hy Lạp - Tiếng Hy Lạp - Εθνικός Οργανισμός Φαρμάκων

sanofi pasteur s.a., lyon, france 2, avenue pont pasteur, 69348 lyon cedex 07 - rabies wistar virus pm/w1 38 1503-3Μ inactivated - ps.inj.sus (ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 2,5 iu/dose - rabies wistar virus pm/w1 38 1503-3Μ inactivated 2,5iu - rabies, inactivated, whole virus

Liên Minh Châu Âu - Tiếng Hy Lạp - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 και 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 και 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Liên Minh Châu Âu - Tiếng Hy Lạp - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - orkambi δισκία ενδείκνυνται για τη θεραπεία της κυστικής ίνωσης (κι) σε ασθενείς ηλικίας 6 ετών και άνω που είναι ομόζυγο για τη μετάλλαξη f508del στο γονίδιο cftr. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Liên Minh Châu Âu - Tiếng Hy Lạp - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Liên Minh Châu Âu - Tiếng Hy Lạp - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Hy Lạp - Tiếng Hy Lạp - Εθνικός Οργανισμός Φαρμάκων

sandoz pharmaceuticals d.d. (abbr. sandoz d.d.), slovenia verovskova 57, si-1000 ljubljana +386 1 580 2111 - salmeterol xinafoate; fluticasone propionate - inh.pd.dos (ΚΟΝΙΣ ΓΙΑ ΕΙΣΠΝΟΗ, ΣΕ ΔΟΣΕΙΣ) - (50+500)mcg/dose - salmeterol xinafoate 0,073mg; fluticasone propionate 0,5mg - salmeterol and fluticasone

Hy Lạp - Tiếng Hy Lạp - Εθνικός Οργανισμός Φαρμάκων

sandoz pharmaceuticals d.d. (abbr. sandoz d.d.), slovenia verovskova 57, si-1000 ljubljana +386 1 580 2111 - salmeterol xinafoate; fluticasone propionate - inh.pd.dos (ΚΟΝΙΣ ΓΙΑ ΕΙΣΠΝΟΗ, ΣΕ ΔΟΣΕΙΣ) - (50+250)mcg/dose - salmeterol xinafoate 0,073mg; fluticasone propionate 0,25mg - salmeterol and fluticasone